Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study

Article

When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).

For patients with nonmetastatic non—small cell lung cancer (NSCLC) who are at intermediate-risk of developing febrile neutropenia (FN), biosimilar filgrastim (Zarxio) is cost-effective when used as a primary prophylaxis (PP) when a payer’s willingness-to-pay (WTP) threshold is $50,000 per quality-adjusted life-year (QALY) gained, according to a new study.

Findings were presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology. Patients with nonmetastatic NSCLC are at intermediate risk (10%-20%) of developing FN if they are receiving platinum-based chemotherapy.

Authors said most patients with NSCLC who receive chemotherapy have ≥1 FN risk factors, and although PP can reduce the incidence of FN, it is more costly than secondary prophylaxis (SP).

The study used a Markov statistical model to evaluate PP versus SP to prevent chemotherapy-induced FN in patients 61 years of age receiving adjuvant carboplatin/paclitaxel every 3 weeks for 4 cycles.

Investigators conducted separate analyses for patients with 0 FN risk factors and ≥1 FN risk factors, representing 11.3% and 18% baseline FN risk, respectively. They calculated incremental cost-effectiveness ratios (ICERs) for cost per FN event avoided, life-year saved (LYS), and QALY gained from a United States payer perspective.

Cost-Effectiveness for Patients

Use of filgrastim as PP versus SP provided an additional 0.056 QALYs (0.079 LYS) for patients with 0 risk factors, at an incremental cost of $3266. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $46,815, $41,555, and $58,531, respectively.

For patients with 1 or more risk factors for FN, PP versus SP added 0.090 QALYs (0.127 LYS) at an incremental cost of $1605. For cost per FN event avoided, cost per LYS, and cost per QALY gained, the ICERs were $13,970, $12,644, and $17,805, respectively.

Investigators also conducted deterministic and probabilistic sensitivity analyses, finding that the likelihood of cost-effectiveness at a WTP threshold of $50,000 per QALY gained was 31.7% for patients with 0 risk factors for FN and 96.6% for those with at least 1 FN risk factor.

Reference

Li EC, Mezzio D, Spargo K, Campbell KJ, Lyman GH. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in non-small cell lung cancer (NSCLC) patients at intermediate risk. Presented at ASCO20 Virtual; May 30-31, 2020. Abstract e19401

Related Videos
Prerakkumar Parikh, PharmD
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Julie Reed
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Related Content
© 2024 MJH Life Sciences

All rights reserved.